CAR-based cell therapies have already reshaped how we think about treating cancer. When these approaches first showed success in blood cancers, it was clear we were seeing something transformative. Engineering immune cells to recognize and eliminate disease was no longer theoretical. It was real, and it was working.
But from the beginning, I believed the potential of CAR-based therapies extended far beyond oncology. Cancer was the first proving ground, not the final destination. Today, we are starting to see how these technologies can be applied to a much broader set of diseases, including autoimmune and neurodegenerative conditions.
Rethinking the Role of the Immune System
To understand where CAR-based therapies are going, we need to rethink the role of the immune system. In cancer, the goal is straightforward. We want immune cells to identify and destroy malignant cells. In other diseases, the objective can be quite different.
In autoimmune diseases, the immune system is overactive or misdirected. Instead of attacking harmful targets, it turns against the body. In neurodegenerative diseases, the challenge is often chronic inflammation or the accumulation of toxic proteins that the immune system fails to clear effectively.
CAR-based approaches allow us to intervene with precision. We can design cells that suppress harmful immune activity, promote repair, or clear damaging material. This flexibility is what makes the platform so powerful.
Moving Beyond CAR-T
Most people associate CAR therapies with CAR-T cells, and for good reason. They have delivered remarkable results in oncology. But as we look beyond cancer, it is clear that other cell types may be better suited for different diseases.
For example, regulatory T cells, or Tregs, offer an opportunity to calm immune responses rather than amplify them. Engineering CAR-Tregs could provide targeted immunosuppression in autoimmune diseases without broadly weakening the immune system.
Macrophages are another promising avenue. These cells play a key role in clearing debris and maintaining tissue health. CAR-modified macrophages could be used to remove toxic proteins in neurodegenerative diseases or reshape inflammatory environments.
The future of CAR therapies will not be defined by a single cell type. It will be a diverse toolkit, with each approach tailored to the biology of the disease.
Challenges in New Indications
While the potential is exciting, expanding CAR therapies beyond oncology comes with significant challenges. Cancer often presents clear targets that distinguish malignant cells from healthy ones. In other diseases, identifying the right target can be more complex.
Safety is also a critical concern. In cancer, aggressive immune activity can be acceptable if it eliminates life-threatening disease. In chronic conditions, the tolerance for side effects is much lower. Therapies must be precise and controlled.
There are also practical challenges. Manufacturing cell therapies at scale remains difficult. Ensuring consistency, quality, and accessibility is essential if these treatments are to reach more patients.
These are not small obstacles, but they are not insurmountable. They require thoughtful science, strong collaboration, and continued innovation.
The Importance of Engineering
One of the most exciting aspects of CAR-based therapies is the ability to engineer cells with increasing sophistication. Early CAR designs were relatively simple. Today, we can build cells that respond to multiple signals, adjust their activity, and persist in the body for longer periods.
This level of control will be especially important outside of oncology. We need cells that can operate in complex and sensitive environments, such as the brain. We need therapies that can adapt over time rather than deliver a single burst of activity.
Advances in gene editing and stem cell technologies are also opening new doors. Induced pluripotent stem cells, or iPSCs, allow us to create standardized, off the shelf cell therapies. This could make CAR-based treatments more accessible and scalable.
A Shift in Development Strategy
Bringing CAR therapies into new disease areas will require a shift in how we approach development. In oncology, rapid and dramatic responses can be observed in relatively short timeframes. In chronic diseases, progress may be slower and more subtle.
Clinical trials will need to be designed differently. Endpoints may focus on slowing disease progression or improving quality of life rather than achieving complete remission. This requires patience and a deep understanding of the disease.
It also requires close collaboration with clinicians and patients. Their insights are essential in defining what meaningful outcomes look like.
Looking Ahead
I believe we are still in the early stages of what CAR-based therapies can achieve. The success in oncology has provided a strong foundation, but the real opportunity lies in expanding these approaches to other areas of medicine.
Neurodegenerative diseases, in particular, represent a major unmet need. Conditions like ALS and multiple sclerosis have limited treatment options, and the impact on patients and families is profound. Applying CAR-based strategies in this space could open entirely new paths for therapy.
At the same time, autoimmune diseases, rare disorders, and even aspects of aging biology may benefit from these approaches. The common thread is the ability to precisely modulate the immune system.
Closing Thoughts
The future of CAR-based cell therapies beyond oncology is both challenging and promising. It will require us to think differently about disease, to embrace complexity, and to push the boundaries of what is possible.
For me, this work is about more than advancing a technology. It is about finding new ways to help patients who currently have limited options. That is what drives the field forward.
We have the tools. We have the knowledge. Now it is a matter of applying them with care, creativity, and purpose.